Paper Details

  1. Home
  2. Paper Details

Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.

Author: AntikainenR, GordinA, HulmiS, KalimaS, MäkeläP

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Erythromycin acistrate (EA) was as effective as enterocoated erythromycin base (EB) in treating acute respiratory tract infections and caused significantly less gastrointestinal side effects.
Paper Details　
Original Abstract of the Article :
The efficacy and tolerability of erythromycin acistrate (EA), a new erythromycin derivative, and enterocoated erythromycin base (EB) were studied in 183 outpatients belonging to the personnel of Helsinki University Central Hospital. The patients had acute respiratory tract infections. The dosage of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/21.suppl_d.85

データ提供：米国国立医学図書館（NLM）

Erythromycin Acistrate: A More Tolerable Option for Respiratory Infections?

This research compares the efficacy and tolerability of two erythromycin formulations, erythromycin acistrate (EA) and enterocoated erythromycin base (EB), in treating acute respiratory infections. The researchers conducted a study to evaluate the effectiveness and side effects of these two medications in outpatients.

EA: A Potential Advantage in Tolerability

The study found that EA was as effective as EB in treating acute respiratory infections. However, EA was associated with significantly fewer gastrointestinal side effects compared to EB. This suggests that EA might be a more tolerable option for patients who experience gastrointestinal discomfort with traditional erythromycin formulations. It's like choosing a camel with a gentler gait for a long desert journey - a smoother ride with fewer bumps along the way.

Navigating Respiratory Infections with Care

This research highlights the importance of individualizing treatment approaches for respiratory infections. Not all medications are created equal, and choosing the right formulation can make a big difference in tolerability. Consulting with a healthcare professional to discuss the best treatment option for your specific needs is crucial. This research provides valuable information for navigating the desert of respiratory infections, helping to find a path to recovery that is as smooth and comfortable as possible.

Dr.Camel's Conclusion

This research is like a camel caravan exploring different pathways through the desert of respiratory infections. It highlights the importance of finding the right medication for your needs, emphasizing the potential benefits of EA for those who experience gastrointestinal discomfort with traditional erythromycin formulations. It's a guide to choosing the right camel for your journey, ensuring a smoother and more comfortable experience as you travel through the desert of illness towards recovery.

Date :
  1. Date Completed 1988-08-24
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

3391879

DOI: Digital Object Identifier

10.1093/jac/21.suppl_d.85

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.